141 related articles for article (PubMed ID: 29331774)
41. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment.
Yu G; Wu Y; Wang W; Xu J; Lv X; Cao X; Wan T
Cell Mol Immunol; 2019 Apr; 16(4):401-409. PubMed ID: 29622799
[TBL] [Abstract][Full Text] [Related]
42. Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
Huang J; Hong M; Zhu Y; Zhao H; Zhang X; Wu Y; Lian Y; Zhao X; Li J; Qian S
Leuk Lymphoma; 2018 Nov; 59(11):2570-2579. PubMed ID: 29616840
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Mar; 11 Suppl 1():S1-6. PubMed ID: 9130684
[TBL] [Abstract][Full Text] [Related]
44. [Effect of High Dose Vitamin C on Proliferation and Apoptosis of Acute Myeloid Leukemia Cells].
Lin XJ; Zou XL; Zhao ZY; Wang J; Yang Z; Ni X; Wei J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):833-841. PubMed ID: 32552944
[TBL] [Abstract][Full Text] [Related]
45. The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review.
van Gorkom GNY; Lookermans EL; Van Elssen CHMJ; Bos GMJ
Nutrients; 2019 Apr; 11(5):. PubMed ID: 31035414
[TBL] [Abstract][Full Text] [Related]
46. Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia.
Guan Y; Greenberg EF; Hasipek M; Chen S; Liu X; Kerr CM; Gackowski D; Zarakowska E; Radivoyevitch T; Gu X; Willard B; Visconte V; Makishima H; Nazha A; Mukherji M; Sekeres MA; Saunthararajah Y; Oliński R; Xu M; Maciejewski JP; Jha BK
Commun Biol; 2020 Sep; 3(1):493. PubMed ID: 32895473
[TBL] [Abstract][Full Text] [Related]
47. Decreased vitamin C uptake mediated by SLC2A3 promotes leukaemia progression and impedes TET2 restoration.
Liu J; Hong J; Han H; Park J; Kim D; Park H; Ko M; Koh Y; Shin DY; Yoon SS
Br J Cancer; 2020 May; 122(10):1445-1452. PubMed ID: 32203209
[TBL] [Abstract][Full Text] [Related]
48. Association of Leukemia Target Genes
Li J; Zhang W; Liu W; Rong J; Chen Y; Gu W; Zhang W
Cancer Genomics Proteomics; 2019; 16(5):333-344. PubMed ID: 31467227
[TBL] [Abstract][Full Text] [Related]
49. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison.
Moertel CG; Fleming TR; Creagan ET; Rubin J; O'Connell MJ; Ames MM
N Engl J Med; 1985 Jan; 312(3):137-41. PubMed ID: 3880867
[TBL] [Abstract][Full Text] [Related]
50. Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes.
Gillberg L; Ørskov AD; Nasif A; Ohtani H; Madaj Z; Hansen JW; Rapin N; Mogensen JB; Liu M; Dufva IH; Lykkesfeldt J; Hajkova P; Jones PA; Grønbæk K
Clin Epigenetics; 2019 Oct; 11(1):143. PubMed ID: 31623675
[TBL] [Abstract][Full Text] [Related]
51. High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients.
Giansanti M; Karimi T; Faraoni I; Graziani G
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804775
[TBL] [Abstract][Full Text] [Related]
52. The function and regulation of TET2 in innate immunity and inflammation.
Cong B; Zhang Q; Cao X
Protein Cell; 2021 Mar; 12(3):165-173. PubMed ID: 33085059
[TBL] [Abstract][Full Text] [Related]
53. Familial myeloid malignancies with germline TET2 mutation.
Duployez N; Goursaud L; Fenwarth L; Bories C; Marceau-Renaut A; Boyer T; Fournier E; Nibourel O; Roche-Lestienne C; Huet G; Beauvais D; Berthon C; Cambier N; Quesnel B; Preudhomme C
Leukemia; 2020 May; 34(5):1450-1453. PubMed ID: 31827242
[No Abstract] [Full Text] [Related]
54. Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy.
Xu YP; Lv L; Liu Y; Smith MD; Li WC; Tan XM; Cheng M; Li Z; Bovino M; Aubé J; Xiong Y
J Clin Invest; 2019 Jul; 129(10):4316-4331. PubMed ID: 31310587
[TBL] [Abstract][Full Text] [Related]
55. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate.
Murata A; Morishige F; Yamaguchi H
Int J Vitam Nutr Res Suppl; 1982; 23():103-13. PubMed ID: 6811475
[TBL] [Abstract][Full Text] [Related]
56. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial.
Creagan ET; Moertel CG; O'Fallon JR; Schutt AJ; O'Connell MJ; Rubin J; Frytak S
N Engl J Med; 1979 Sep; 301(13):687-90. PubMed ID: 384241
[TBL] [Abstract][Full Text] [Related]
57. Intravenous Vitamin C for Cancer Therapy - Identifying the Current Gaps in Our Knowledge.
Carr AC; Cook J
Front Physiol; 2018; 9():1182. PubMed ID: 30190680
[TBL] [Abstract][Full Text] [Related]
58. Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach.
Klimant E; Wright H; Rubin D; Seely D; Markman M
Curr Oncol; 2018 Apr; 25(2):139-148. PubMed ID: 29719430
[TBL] [Abstract][Full Text] [Related]
59. High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer.
Böttger F; Vallés-Martí A; Cahn L; Jimenez CR
J Exp Clin Cancer Res; 2021 Oct; 40(1):343. PubMed ID: 34717701
[TBL] [Abstract][Full Text] [Related]
60. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer.
Cameron E; Campbell A
Chem Biol Interact; 1974 Oct; 9(4):285-315. PubMed ID: 4430016
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
